Impact of surgical volume on complete gross resection rates for women with advanced stage epithelial ovarian carcinoma

2018 ◽  
Vol 149 ◽  
pp. 86-87
Author(s):  
D. Nasioudis ◽  
B.B. Albright ◽  
E. Chapman-Davis ◽  
M.K. Frey ◽  
T.A. Caputo ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinoma ◽  
Advanced Stage ◽  
Surgical Volume

Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma

2019 ◽  
Vol 154 (2) ◽  
pp. 401-404 ◽  
Author(s):  
Dimitrios Nasioudis ◽  
Ryan Kahn ◽  
Eloise Chapman-Davis ◽  
Melissa K. Frey ◽  
Thomas A. Caputo ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinoma ◽  
Advanced Stage ◽  
Surgical Volume ◽  
Debulking Surgery ◽  
Primary Debulking Surgery

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study

2005 ◽  
Vol 15 (2) ◽  
pp. 217-223 ◽  
Author(s):  
V. Loizzi ◽  
G. Cormio ◽  
L. Resta ◽  
C. A. Rossi ◽  
A. R. Di Gilio ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Performance Status ◽  
Disease Free Survival ◽  
Epithelial Ovarian Carcinoma ◽  
Advanced Stage ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Platinum Based Chemotherapy

The aim of this study was to compare the outcome of patients with advanced ovarian carcinoma treated with neoadjuvant chemotherapy (NACT) with those treated conventionally with primary debulking surgery. From 1994 to 2003, all consecutive cases of advanced-stage epithelial ovarian carcinoma treated with NACT at the University of Bari were identified. A well-balanced group of women who underwent primary debulking surgery followed by platinum-based chemotherapy was selected as controls. Kaplan–Meier and Cox proportional hazards analyses were used to determine the predictors for survival. Thirty women with advanced-stage epithelial ovarian carcinoma were treated with NACT and compared to 30 patients who underwent primary debulking surgery. Patients in the NACT were significantly older and had a poorer performance status compared to the controls. However, no statistical difference was observed in overall disease-specific survival (P = 0.66) and disease-free survival (P = 0.25) between the two groups. Although patients in the NACT group are significantly older and have a poorer performance status, this treatment modality does not compromise survival. Prospective randomized trials comparing NACT to conventional treatment to determine the quality of life and cost/benefit outcomes are now appropriate for women presenting advanced epithelial ovarian cancer.

scholarly journals Fascin Expression as Prognostic Factor for Survival in Advanced Epithelial Ovarian Carcinoma

2016 ◽  
Author(s):  
Fara Vitantri ◽  
Sigit Purbadi ◽  
Budiningsih Siregar ◽  
Bambang Sutrisna
Keyword(s):  
Prognostic Factor ◽  
Ovarian Carcinoma ◽  
Obstet Gynecol ◽  
Epithelial Ovarian Carcinoma ◽  
Advanced Stage ◽  
Confounding Factors ◽  
Historical Cohort ◽  
Cohort Design ◽  
Paraffin Block ◽  
Clinicopathologic Factors

Objective: To evaluate fascin expression as a prognostic factor and its correlation with survival and clinicopathologic factors (degree of differentiation and stage) in epithelial ovarian carcinoma. Methods: This study is prognostic study with historical cohort design. Fascin was analyzed in paraffin block sections of 33 advanced stage ovarian carcinoma patients using immunohistochemistry. Fascin expression was tested for its correlation with overall survival as well as with grade and stage of the cancer. Results: In this study, fascin expression has no correlation with survival. In the period of 17-22 months, samples with high fascin expression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the period of 17-23 months, both groups had comparable HR. In the period of more than 23 months, samples with high expression of fascin had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant correlation was found between fascin expression with grade (OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95% CI=0.39-18.96, p=0.360). Conclusion: In this study, there was no correlation between fascin expression and survival, and also no correlation between fascin, grade and stage. Further study with a larger, more homogenous sample, analyzing confounding factors is needed. [Indones J Obstet Gynecol 2015; 3-4: 222-229] Keywords: advanced stage ovarian carcinoma, fascin, survival

The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

2009 ◽  
Vol 116 (3) ◽  
pp. 372-380 ◽  
Author(s):  
CG Gerestein ◽  
MJC Eijkemans ◽  
D de Jong ◽  
MEL van der Burg ◽  
RHM Dykgraaf ◽  
...  
Keyword(s):  
Overall Survival ◽  
Ovarian Carcinoma ◽  
Epithelial Ovarian Carcinoma ◽  
Advanced Stage

scholarly journals Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study

2021 ◽  
Vol 18 (12) ◽  
pp. 6629
Author(s):  
Hsin-Ying Huang ◽  
Chun-Ju Chiang ◽  
Yun-Yuan Chen ◽  
San-Lin You ◽  
Heng-Cheng Hsu ◽  
...  
Keyword(s):  
Overall Survival ◽  
Ovarian Carcinoma ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Epithelial Ovarian Carcinoma ◽  
The Other ◽  
Research Database ◽  
Advanced Stage ◽  
Hazard Ratios ◽  
First Choice

We aimed to evaluate factors influencing the outcomes of patients with platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Patients with advanced-stage EOC, who received debulking surgery and adjuvant chemotherapy for recurrence, were obtained from the National Health Insurance Research database of Taiwan between 2000 and 2013. A total of 1038 patients with recurrent advanced-stage EOC were recruited. The platinum + paclitaxel (PT) group had the best five-year overall survival (OS) compared with the other three groups (p < 0.001). The hazard ratios (HRs) of five-year OS for the platinum + liposomal doxorubicin (PD), topotecan (TOP), and pegylated liposomal doxorubicin (PLD) groups were 1.21 (p = 0.07), 1.35 (p = 0.016), and 1.80 (p < 0.001), respectively, compared with the PT group. The PT group also had lower hazard ratios of five-year OS for patients with platinum therapy-free interval (TFIp) between 6 and 12 months compared with the other three groups (p < 0.0001). However, the HRs of five-year OS did not differ between the PT and PD groups in patients with TFIp >12 months. Patients with TFIp >12 months had lower HRs of five-year OS compared with those with TFIp of 6–12 months, regardless of whether they were treated with platinum-based (p = 0.001) or non-platinum-based (p = 0.003) regimens. Chemotherapeutic regimens and TFIp influenced the outcomes of patients with recurrent EOC. For patients with TFIp of 6–12 months, the PT regimen is the first choice based on their best overall survival result. For patients with TFIp >12 months, either platinum-based or non-platinum regimens could be used because of their similar excellent overall survival.

Sign in / Sign up

Export Citation Format

Share Document